{ "instance": { "acrx20211231_10k.htm": { "axisCustom": 0, "axisStandard": 37, "contextCount": 270, "dts": { "calculationLink": { "local": [ "acrx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "acrx-20211231_def.xml" ] }, "inline": { "local": [ "acrx20211231_10k.htm" ] }, "labelLink": { "local": [ "acrx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "acrx-20211231_pre.xml" ] }, "schema": { "local": [ "acrx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 650, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 39, "http://www.acelrx.com/20211231": 12, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 57 }, "keyCustom": 89, "keyStandard": 408, "memberCustom": 55, "memberStandard": 45, "nsprefix": "acrx", "nsuri": "http://www.acelrx.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.acelrx.com/20211231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Property and Equipment, Net", "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net", "shortName": "Note 4 - Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:InlicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - In-license Agreement", "role": "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "shortName": "Note 5 - In-license Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:InlicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:OutlicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Out-license Agreements", "role": "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "shortName": "Note 6 - Out-license Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:OutlicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Revenue From Contracts With Customers", "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "shortName": "Note 7 - Revenue From Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Long-term Debt", "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "shortName": "Note 8 - Long-term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Leases", "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases", "shortName": "Note 9 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties", "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "shortName": "Note 10 - Liability Related to Sale of Future Royalties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Warrants", "role": "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "shortName": "Note 11 - Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Commitments and Contingencies", "role": "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "shortName": "Note 12 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Stockholders' Equity", "role": "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "shortName": "Note 13 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Stock Based Compensation", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "shortName": "Note 14 - Stock Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 15 - Net Loss Per Share of Common Stock", "role": "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock", "shortName": "Note 15 - Net Loss Per Share of Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 16 - Accrued Liabilities", "role": "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities", "shortName": "Note 16 - Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 17 - 401(k) Plan", "role": "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan", "shortName": "Note 17 - 401(k) Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 18 - Income Taxes", "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "shortName": "Note 18 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 19 - Subsequent Events", "role": "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "shortName": "Note 19 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Schedule II - Valuation and Qualifying Accounts", "role": "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts", "shortName": "Schedule II - Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:BusinessDescriptionOfEntityPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:BusinessDescriptionOfEntityPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 2 - Investments and Fair Value Measurement (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables", "shortName": "Note 2 - Investments and Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 3 - Inventories, Net (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables", "shortName": "Note 3 - Inventories, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 4 - Property and Equipment, Net (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables", "shortName": "Note 4 - Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 7 - Revenue From Contracts With Customers (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables", "shortName": "Note 7 - Revenue From Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 8 - Long-term Debt (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables", "shortName": "Note 8 - Long-term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 9 - Leases (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables", "shortName": "Note 9 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables", "shortName": "Note 10 - Liability Related to Sale of Future Royalties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 14 - Stock Based Compensation (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables", "shortName": "Note 14 - Stock Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 15 - Net Loss Per Share of Common Stock (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables", "shortName": "Note 15 - Net Loss Per Share of Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 16 - Accrued Liabilities (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables", "shortName": "Note 16 - Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 18 - Income Taxes (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables", "shortName": "Note 18 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:ValuationAllowancesAndReservesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)", "role": "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables", "shortName": "Schedule II - Valuation and Qualifying Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:ValuationAllowancesAndReservesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2020-03-16_2020-03-16", "decimals": "INF", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 2 - Investments and Fair Value Measurement (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual", "shortName": "Note 2 - Investments and Fair Value Measurement (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details", "shortName": "Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "shortName": "Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details", "shortName": "Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2019-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 3 - Inventories, Net (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "shortName": "Note 3 - Inventories, Net (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_ProductOrServiceAxis-AmendedLicenseAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 3 - Inventories, Net - Inventory Components (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details", "shortName": "Note 3 - Inventories, Net - Inventory Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual", "shortName": "Note 4 - Property and Equipment, Net (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Stockholders' Deficit", "role": "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "shortName": "Consolidated Statements of Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details", "shortName": "Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "acrx:InlicenseAgreementTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember", "decimals": "-6", "first": true, "lang": null, "name": "acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 5 - In-license Agreement (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "shortName": "Note 5 - In-license Agreement (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrx:InlicenseAgreementTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember", "decimals": "-6", "first": true, "lang": null, "name": "acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 6 - Out-license Agreements (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "shortName": "Note 6 - Out-license Agreements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrx:OutlicenseAgreementTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember", "decimals": "-5", "lang": null, "name": "acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 7 - Revenue From Contracts With Customers (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "shortName": "Note 7 - Revenue From Contracts With Customers (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember", "decimals": "-5", "lang": null, "name": "acrx:LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "shortName": "Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ProductOrServiceAxis-DSUVIAMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "shortName": "Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 8 - Long-term Debt (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual", "shortName": "Note 8 - Long-term Debt (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details", "shortName": "Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-03-26_2021-03-26", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainLossOnTerminationOfLease", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 9 - Leases (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual", "shortName": "Note 9 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2012-12-12_2012-12-12", "decimals": "-5", "lang": null, "name": "acrx:LesseeOperatingLeaseAnnualOverheadFeePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 9 - Leases - Operating Lease Costs (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details", "shortName": "Note 9 - Leases - Operating Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 9 - Leases - Maturities of Lease Liabilities (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details", "shortName": "Note 9 - Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2015-09-18_2015-09-18", "decimals": "-6", "first": true, "lang": null, "name": "acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual", "shortName": "Note 10 - Liability Related to Sale of Future Royalties (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-6", "lang": null, "name": "acrx:ContingentGainLossOnRoyaltyMonetizationArrangement", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "acrx:LiabilityRelatedToSaleOfFutureRoyalties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "shortName": "Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "acrx:LiabilityRelatedToSaleOfFutureRoyalties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 11 - Warrants (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "shortName": "Note 11 - Warrants (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember", "decimals": "-6", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual", "shortName": "Note 12 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 13 - Stockholders' Equity (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "shortName": "Note 13 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-11-17", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 14 - Stock Based Compensation (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "shortName": "Note 14 - Stock Based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details", "shortName": "Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "shortName": "Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 14 - Stock Based Compensation - Option Activity (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "shortName": "Note 14 - Stock Based Compensation - Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies", "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "true" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details", "shortName": "Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "true" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "shortName": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "shortName": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details", "shortName": "Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 16 - Accrued Liabilities - Accrued Liabilities (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details", "shortName": "Note 16 - Accrued Liabilities - Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2019-01-01_2019-12-31", "decimals": "2", "first": true, "lang": null, "name": "acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note 17 - 401(k) Plan (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual", "shortName": "Note 17 - 401(k) Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2019-01-01_2019-12-31", "decimals": "2", "first": true, "lang": null, "name": "acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note 18 - Income Taxes (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "shortName": "Note 18 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note 18 - Income Taxes - Net Deferred Tax Assets (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details", "shortName": "Note 18 - Income Taxes - Net Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details", "shortName": "Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)", "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details", "shortName": "Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Investments and Fair Value Measurement", "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement", "shortName": "Note 2 - Investments and Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AcquisitionCostsCumulative", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Note 19 - Subsequent Events (Details Textual)", "role": "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "shortName": "Note 19 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AcquisitionCostsCumulative", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "acrx:ValuationAllowancesAndReservesTableTextBlock", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)", "role": "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details", "shortName": "Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "acrx:ValuationAllowancesAndReservesTableTextBlock", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Inventories, Net", "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "shortName": "Note 3 - Inventories, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acrx20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 101, "tag": { "acrx_ATMAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to at the market agreement.", "label": "ATM Agreement [Member]" } } }, "localname": "ATMAgreementMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "acrx_AccruedDeferredRevenueCurrent": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for deferred revenue. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "acrx_AccruedDeferredRevenueCurrent", "terseLabel": "Deferred revenue" } } }, "localname": "AccruedDeferredRevenueCurrent", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "acrx_AccruedProductReturnsAndSalesAllowancesCurrent": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued product returns and sales allowance.", "label": "Accrued product returns and sales allowances" } } }, "localname": "AccruedProductReturnsAndSalesAllowancesCurrent", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "acrx_AcelRXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entity AcelRX.", "label": "AcelRX [Member]" } } }, "localname": "AcelRXMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "domainItemType" }, "acrx_AcelrxCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents AcelRx common stock.", "label": "AcelRx Common Stock [Member]" } } }, "localname": "AcelrxCommonStockMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "acrx_AggregateOfferingPriceIncreaseDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate offering price increase during period.", "label": "acrx_AggregateOfferingPriceIncreaseDuringPeriod", "terseLabel": "Aggregate Offering Price, Increase During Period" } } }, "localname": "AggregateOfferingPriceIncreaseDuringPeriod", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_AggregateOfferingPriceMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum aggregate offering price.", "label": "acrx_AggregateOfferingPriceMaximum", "terseLabel": "Aggregate Offering Price, Maximum" } } }, "localname": "AggregateOfferingPriceMaximum", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_AguettantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Aguettant.", "label": "Aguettant [Member]" } } }, "localname": "AguettantMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "domainItemType" }, "acrx_AmendedLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended License Agreement", "label": "Amended License Agreement [Member]" } } }, "localname": "AmendedLicenseAgreementMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "domainItemType" }, "acrx_ArmisticeCapitalAndRockSpringsCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Armistice Capital and Rock Springs Capital.", "label": "Armistice Capital and Rock Springs Capital [Member]" } } }, "localname": "ArmisticeCapitalAndRockSpringsCapitalMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of asset acquisition costs in accounts payable and accrued expenses.", "label": "Asset acquisition costs in accounts payable and accrued expenses" } } }, "localname": "AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_BasedUponNetSalesTargetAchievementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount, or portion of an amount, that is, will be, or may be based upon \"net sales target achievements.\"", "label": "Based upon Net Sales Target Achievements [Member]" } } }, "localname": "BasedUponNetSalesTargetAchievementsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "domainItemType" }, "acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount, or portion of an amount, that is, will be, or may be based upon \"successful regulatory and product development efforts.\"", "label": "Based upon Successful Regulatory and Product Development Efforts [Member]" } } }, "localname": "BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "domainItemType" }, "acrx_BeforeTaxYear2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as before tax year 2018.", "label": "Before Tax Year 2018 [Member]" } } }, "localname": "BeforeTaxYear2018Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents acquiree common stock to be held back to satisfy some obligations.", "label": "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations", "terseLabel": "Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)" } } }, "localname": "BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents acquiree common stock to be held back to satisfy some obligations, fixed value per share.", "label": "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare", "terseLabel": "Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share)" } } }, "localname": "BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, net of the cash acquired from the purchase.", "label": "acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired", "terseLabel": "Business Combination, Consideration Transferred, Net of Cash Acquired" } } }, "localname": "BusinessCombinationConsiderationTransferredNetOfCashAcquired", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of options to purchase capital stock and all shares of capital stock issued and outstanding in exchange for cash.", "label": "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash", "terseLabel": "Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash" } } }, "localname": "BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents options to purchase capital stock and all shares of stock issued and outstanding cancelled in exchange for right to receive common stock.", "label": "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber", "terseLabel": "Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares)" } } }, "localname": "BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "acrx_BusinessDescriptionOfEntityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the accounting policy regarding the business description of entity.", "label": "Business Description of Entity [Policy Text Block]" } } }, "localname": "BusinessDescriptionOfEntityPolicyTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, and marketable securities including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash, Cash Equivalents, and Marketable Securities [Policy Text Block]" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents fair value of cash, cash equivalents and short-term investments.", "label": "Total cash, cash equivalents and short-term investments, fair value" } } }, "localname": "CashCashEquivalentsAndShorttermInvestmentsFairValue", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "acrx_CatalentPharmaSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Catalent Pharma Solutions, LLC, or Catalent.", "label": "Catalent Pharma Solutions [Member]" } } }, "localname": "CatalentPharmaSolutionsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents required percentage of ownership in order for warrants become exercisable.", "label": "acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable", "terseLabel": "Class of Warrant or Right, Required Percentage of Ownership to Become Exercisable" } } }, "localname": "ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "percentItemType" }, "acrx_CommercialMilestonesValueMaximumAmountAvailable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum value of commercial milestone payments available to the company.", "label": "acrx_CommercialMilestonesValueMaximumAmountAvailable", "terseLabel": "Commercial Milestones Value Maximum Amount Available" } } }, "localname": "CommercialMilestonesValueMaximumAmountAvailable", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Computer Equipment and Software.", "label": "Computer Equipment and Software [Member]" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "acrx_ContingentGainLossOnRoyaltyMonetizationArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of contingent gain (loss) on royalty monetization arrangement.", "label": "acrx_ContingentGainLossOnRoyaltyMonetizationArrangement", "terseLabel": "Contingent Gain (Loss) on Royalty Monetization Arrangement" } } }, "localname": "ContingentGainLossOnRoyaltyMonetizationArrangement", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_ContingentPutOptionLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the contingent put option liability.", "label": "Contingent Put Option Liability [Member]" } } }, "localname": "ContingentPutOptionLiabilityMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "domainItemType" }, "acrx_ContingentPutOptionPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding one or more contingent put options of the Company.", "label": "Contingent Put Option, Policy [Policy Text Block]" } } }, "localname": "ContingentPutOptionPolicyPolicyTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "acrx_ContractAndOtherCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents contract and other collaboration.", "label": "Contract and Other Collaboration [Member]" } } }, "localname": "ContractAndOtherCollaborationMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "acrx_ContractAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Contract and Other Revenue.", "label": "Contract and Other Revenue [Member]" } } }, "localname": "ContractAndOtherRevenueMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "acrx_ContractWithCustomerLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer.", "label": "Additions(2)" } } }, "localname": "ContractWithCustomerLiabilityAdditions", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" ], "xbrltype": "monetaryItemType" }, "acrx_ContractWithCustomerLiabilityLiabilityEliminated": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the contract with customer liability eliminated.", "label": "acrx_ContractWithCustomerLiabilityLiabilityEliminated", "terseLabel": "Contract with Customer, Liability, Liability Eliminated" } } }, "localname": "ContractWithCustomerLiabilityLiabilityEliminated", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents contract with customer liability revenue recognized during current period,", "label": "acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod", "negatedLabel": "In current period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" ], "xbrltype": "monetaryItemType" }, "acrx_ContributionsByEmployerToPostemploymentBenefitObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "acrx_ContributionsByEmployerToPostemploymentBenefitObligations", "terseLabel": "Contributions by Employer to Postemployment Benefit Obligations" } } }, "localname": "ContributionsByEmployerToPostemploymentBenefitObligations", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to customer A.", "label": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "acrx_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to customer B.", "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "acrx_DSUVIAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents DSUVIA.", "label": "DSUVIA [Member]" } } }, "localname": "DSUVIAMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "acrx_DZUVEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to DZUVEO.", "label": "DZUVEO [Member]" } } }, "localname": "DZUVEOMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "domainItemType" }, "acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of unrestricted cash required to be maintained by the debt agreement.", "label": "acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash", "terseLabel": "Debt Instrument, Covenant, Minimum Required Unrestircted Cash" } } }, "localname": "DebtInstrumentCovenantMinimumRequiredUnrestirctedCash", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_DebtInstrumentDefaultAdditionalInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the default additional interest rate for debt instrument.", "label": "acrx_DebtInstrumentDefaultAdditionalInterestRate", "terseLabel": "Debt Instrument, Default Additional Interest Rate" } } }, "localname": "DebtInstrumentDefaultAdditionalInterestRate", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "percentItemType" }, "acrx_DebtInstrumentInterestRateBasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual base interest rate for funds borrowed, under the debt agreement.", "label": "acrx_DebtInstrumentInterestRateBasePercentage", "terseLabel": "Debt Instrument, Interest Rate, Base Percentage" } } }, "localname": "DebtInstrumentInterestRateBasePercentage", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "percentItemType" }, "acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents minimum indebtedness amount with acceleration right under debt instrument.", "label": "acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight", "terseLabel": "Debt Instrument, Minimum Indebtedness Amount with Acceleration Right" } } }, "localname": "DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_DebtInstrumentUnamortizedEotFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents debt instrument unamortized EOT fee.", "label": "acrx_DebtInstrumentUnamortizedEotFee", "negatedLabel": "Less: Unamortized portion of EOT Fee" } } }, "localname": "DebtInstrumentUnamortizedEotFee", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accruals and other" } } }, "localname": "DeferredTaxAssetsAccruedLiabilitiesAndOther", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Percentage" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionPercentage", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual" ], "xbrltype": "percentItemType" }, "acrx_DoDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to DoD.", "label": "DoD [Member]" } } }, "localname": "DoDMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "acrx_EffectiveAnnualInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective annual rate for a liability related to sale of future royalties.", "label": "acrx_EffectiveAnnualInterestRate", "terseLabel": "Effective Annual Interest Rate" } } }, "localname": "EffectiveAnnualInterestRate", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "percentItemType" }, "acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of effective interest over the life of the liability related to sale of future royalties.", "label": "acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties", "terseLabel": "Effective Interest Over Life of Liability Related to Sale of Future Royalties" } } }, "localname": "EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "percentItemType" }, "acrx_EmployeeStockPurchasePlanESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the employee stock purchase plan.", "label": "Employee Stock Purchase Plan (ESPP) [Member]" } } }, "localname": "EmployeeStockPurchasePlanESPPMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average fair value of shares issued under an ESPP.", "label": "acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue", "terseLabel": "Employee Stock Purchase Plan, Shares Issued, Weighted Average Fair Value (in dollars per share)" } } }, "localname": "EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "acrx_EquityIncentivePlan2011Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name or description of the plan.", "label": "2011 Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlan2011Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "acrx_EstimatedOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of estimated offering costs.", "label": "acrx_EstimatedOfferingCosts", "terseLabel": "Estimated Offering Costs" } } }, "localname": "EstimatedOfferingCosts", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the first exercise price range.", "label": "Exercise Price Range 1 [Member]" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "acrx_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the second exercise price range.", "label": "Exercise Price Range 2 [Member]" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "acrx_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the third exercise price range.", "label": "Exercise Price Range 3 [Member]" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "acrx_ExercisePriceRange4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the fourth exercise price range.", "label": "Exercise Price Range 4 [Member]" } } }, "localname": "ExercisePriceRange4Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "acrx_ExercisePriceRange5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the fifth exercise price range.", "label": "Exercise Price Range 5 [Member]" } } }, "localname": "ExercisePriceRange5Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "acrx_ExercisePriceRange6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the sixth exercise price range.", "label": "Exercise Price Range 6 [Member]" } } }, "localname": "ExercisePriceRange6Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "acrx_FairValueOfContingentPutOptionLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value of contingent put option liability.", "label": "acrx_FairValueOfContingentPutOptionLiability", "terseLabel": "Fair Value of Contingent Put Option, Liability" } } }, "localname": "FairValueOfContingentPutOptionLiability", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_FirstFourCommercialMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the detail of parts of royalties and rights received.", "label": "First Four Commercial Milestones [Member]" } } }, "localname": "FirstFourCommercialMilestonesMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "domainItemType" }, "acrx_GainLossOnTerminationOfSublease": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of sublease.", "label": "acrx_GainLossOnTerminationOfSublease", "negatedLabel": "Loss on termination of sublease" } } }, "localname": "GainLossOnTerminationOfSublease", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "monetaryItemType" }, "acrx_GainOnTerminationOfSublease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain on termination of sublease.", "label": "Gain on termination of sublease" } } }, "localname": "GainOnTerminationOfSublease", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_GrunenthalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name or description of the counterparty.", "label": "Grunenthal [Member]" } } }, "localname": "GrunenthalMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "acrx_InlicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for in-license agreement.", "label": "In-license Agreement [Text Block]" } } }, "localname": "InlicenseAgreementTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement" ], "xbrltype": "textBlockItemType" }, "acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of investments and fair value measurement.", "label": "Investments and Fair Value Measurement Disclosure [Text Block]" } } }, "localname": "InvestmentsAndFairValueMeasurementDisclosureTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement" ], "xbrltype": "textBlockItemType" }, "acrx_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Laboratory Equipment.", "label": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the lease agreement for the corporate headquarters in Hayward, California.", "label": "Lease for Corporate Headquarters in Hayward, California [Member]" } } }, "localname": "LeaseForCorporateHeadquartersInHaywardCaliforniaMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "acrx_LeaseholdPaidWithNotePayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents leasehold paid with note payable.", "label": "Leasehold improvements paid with note payable" } } }, "localname": "LeaseholdPaidWithNotePayable", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_LesseeOperatingLeaseAbatedRentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of abated rent of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "acrx_LesseeOperatingLeaseAbatedRentPeriod", "terseLabel": "Lessee, Operating Lease, Abated Rent Period (Month)" } } }, "localname": "LesseeOperatingLeaseAbatedRentPeriod", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "durationItemType" }, "acrx_LesseeOperatingLeaseAnnualOverheadFeePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of required fee payments per year for overhead, prorated based on aggregate revenues.", "label": "acrx_LesseeOperatingLeaseAnnualOverheadFeePayments", "terseLabel": "Lessee, Operating Lease, Annual Overhead Fee Payments" } } }, "localname": "LesseeOperatingLeaseAnnualOverheadFeePayments", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LesseeOperatingLeaseMonthlyRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the monthly rent required for operating lease.", "label": "acrx_LesseeOperatingLeaseMonthlyRent", "terseLabel": "Lessee, Operating Lease, Monthly Rent" } } }, "localname": "LesseeOperatingLeaseMonthlyRent", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LesseeOperatingLeaseNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease termination notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "acrx_LesseeOperatingLeaseNoticePeriod", "terseLabel": "Lessee, Operating Lease, Notice Period (Year)" } } }, "localname": "LesseeOperatingLeaseNoticePeriod", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "durationItemType" }, "acrx_LesseeOperatingSubleaseDeferredCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for operating sublease deferred costs.", "label": "acrx_LesseeOperatingSubleaseDeferredCosts", "terseLabel": "Lessee, Operating Sublease, Deferred Costs" } } }, "localname": "LesseeOperatingSubleaseDeferredCosts", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LiabilityRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents liability related to future royalties.", "label": "acrx_LiabilityRelatedToSaleOfFutureRoyalties", "periodStartLabel": "Liability related to sale of future royalties \u2014 beginning balance" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" ], "xbrltype": "monetaryItemType" }, "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for liability related to sale of future royalties.", "label": "Liability Related To Sale Of Future Royalties Disclosure [Text Block]" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties" ], "xbrltype": "textBlockItemType" }, "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of liability related to sale of future royalties less current portion.", "label": "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet", "periodEndLabel": "Liability related to sale of future royalties as of December 31, 2021" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNet", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" ], "xbrltype": "monetaryItemType" }, "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability related to sale of future royalities classified as noncurrent.", "label": "Liability related to the sale of future royalties" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents milestone payments and revenue share payments to be received for license agreement.", "label": "acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived", "terseLabel": "License Agreement, Milestone Payments and Revenue Share Payments to be Received" } } }, "localname": "LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum amount of milestone payments to be paid under license agreement.", "label": "acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum", "terseLabel": "License Agreement, Milestone Payments to be Paid, Maximum" } } }, "localname": "LicenseAgreementMilestonePaymentsToBePaidMaximum", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LicenseAgreementMinimumSalesObligationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the minimum sales obligation term under license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "acrx_LicenseAgreementMinimumSalesObligationTerm", "terseLabel": "License Agreement, Minimum Sales Obligation Term (Month)" } } }, "localname": "LicenseAgreementMinimumSalesObligationTerm", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" ], "xbrltype": "durationItemType" }, "acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenue share payments to be paid under license agreement.", "label": "acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid", "terseLabel": "License Agreement, Percent of Revenue Share Payment to be Paid" } } }, "localname": "LicenseAgreementPercentOfRevenueSharePaymentToBePaid", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" ], "xbrltype": "percentItemType" }, "acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenue share payments to be received under license agreement.", "label": "acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived", "terseLabel": "License Agreement, Percent of Revenue Share Payments to be Received" } } }, "localname": "LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "percentItemType" }, "acrx_LicenseAgreementRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The renewal term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "acrx_LicenseAgreementRenewalTerm", "terseLabel": "License Agreement, Renewal Term (Year)" } } }, "localname": "LicenseAgreementRenewalTerm", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "durationItemType" }, "acrx_LicenseAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "acrx_LicenseAgreementTerm", "terseLabel": "License Agreement, Term (Year)" } } }, "localname": "LicenseAgreementTerm", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "durationItemType" }, "acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the upfront payments and the maximum amount of milestone payments to be received under license agreement.", "label": "acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived", "terseLabel": "License Agreement, Upfront and Maximum Milestone Payments to be Received" } } }, "localname": "LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LoanAgreementWithOxfordFinanceLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to loan agreement with Oxford Finance LLC.", "label": "Loan Agreement with Oxford Finance LLC [Member]" } } }, "localname": "LoanAgreementWithOxfordFinanceLLCMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the trigger of negative impact of government approvals and judgments for loan default events.", "label": "acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments", "terseLabel": "Loan Default Events, Trigger of Negative Impact of Government Approvals and Judgments" } } }, "localname": "LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "order": 1.0, "parentTag": "acrx_LongTermDebtTotalMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum payments for both principal and interest on long-term debt to be paid in the second fiscal year following the latest fiscal year.", "label": "2022" } } }, "localname": "LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "acrx_LongTermDebtMaturitiesRepaymentsOfInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the interest portion of future minimum payments on long-term debt.", "label": "acrx_LongTermDebtMaturitiesRepaymentsOfInterest", "negatedLabel": "Less amount representing interest" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfInterest", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "acrx_LongTermDebtTotalMinimumPayments": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the future minimum payments on long-term debt, including both principal and interest.", "label": "acrx_LongTermDebtTotalMinimumPayments", "totalLabel": "Total payments" } } }, "localname": "LongTermDebtTotalMinimumPayments", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "order": 0.0, "parentTag": "acrx_LongTermDebtTotalMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum payments for both principal and interest on long-term debt to be paid in the third fiscal year following the latest fiscal year.", "label": "2023" } } }, "localname": "LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "acrx_LowellTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Lowell Therapeutics.", "label": "Lowell Therapeutics [Member]" } } }, "localname": "LowellTherapeuticsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "acrx_LowellsIntellectualPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Lowell\u2019s intellectual property.", "label": "Lowell\u2019s Intellectual Property [Member]" } } }, "localname": "LowellsIntellectualPropertyMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "acrx_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents marketable securities.", "label": "Marketable Securities [Member]" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock and exercise of warrants.", "label": "acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants", "terseLabel": "Net Proceeds from Issuance of Common Stock and Exercise of Warrants" } } }, "localname": "NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_NetProceedsFromSaleOfFutureRoyalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds from sale of future royalties.", "label": "Proceeds from sale of future royalties", "terseLabel": "Net Proceeds from Sale of Future Royalties" } } }, "localname": "NetProceedsFromSaleOfFutureRoyalties", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_NonCashRoyaltyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about non-cash royalty.", "label": "Non-cash Royalty [Member]" } } }, "localname": "NonCashRoyaltyMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of non-cash royalty revenue recognized in connection to royalty monetization.", "label": "acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization", "negatedLabel": "Non-cash royalty revenue related to royalty monetization" } } }, "localname": "NonCashRoyaltyRevenueRelatedToRoyaltyMonetization", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_NoncashInterestExpenseRecognized": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non-cash interest expense recognized.", "label": "Non-cash interest income on liability related to royalty monetization" } } }, "localname": "NoncashInterestExpenseRecognized", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amoutn of noncash interest income expense on liability related to sale of future royalties.", "label": "Non-cash interest income on liability related to sale of future royalties", "negatedTerseLabel": "Non-cash interest (income) expense recognized" } } }, "localname": "NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" ], "xbrltype": "monetaryItemType" }, "acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of non-cash royalty revenue recognized in connection to royalty monetization that has been realized.", "label": "acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized", "negatedTerseLabel": "Non-cash royalty revenue" } } }, "localname": "NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" ], "xbrltype": "monetaryItemType" }, "acrx_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_NotesPayableGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, after subtracting the amount representing interest but before subtracting any balloon payment(s) or unamortized discount, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable, gross" } } }, "localname": "NotesPayableGross", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "acrx_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_November2021FinancingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "represents November 2021 Financing Warrants.", "label": "November 2021 Financing Warrants [Member]" } } }, "localname": "November2021FinancingWarrantsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "acrx_OUMCoLLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the auditor, OUM & CO. LLP.", "label": "OUM & CO. LLP [Member]" } } }, "localname": "OUMCoLLPMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "acrx_OutlicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of out-license agreement.", "label": "Out-license Agreement [Text Block]" } } }, "localname": "OutlicenseAgreementTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements" ], "xbrltype": "textBlockItemType" }, "acrx_PFSProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to PFS products.", "label": "PFS Products [Member]" } } }, "localname": "PFSProductsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" ], "xbrltype": "domainItemType" }, "acrx_PercentageOfRoyaltiesAndRightsUnderAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of royalties or milestone rights to be received under the agreement.", "label": "acrx_PercentageOfRoyaltiesAndRightsUnderAgreement", "terseLabel": "Percentage of Royalties and Rights Under Agreement" } } }, "localname": "PercentageOfRoyaltiesAndRightsUnderAgreement", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "percentItemType" }, "acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of outstanding balance for repayment charge if prepayment occurs after May 30, 2020 and before May 30, 2021.", "label": "acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021", "terseLabel": "Prepayment Charge, Percentage of Outstanding Balance, After May 30, 2020, Before May 30, 2021" } } }, "localname": "PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "percentItemType" }, "acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow from up-front and share-based millstone license payments.", "label": "acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments", "terseLabel": "Proceeds form Up-front and Sales-based Milestone License Payments" } } }, "localname": "ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of debt, net of issuance costs paid to third parties and repayments of debt.", "label": "acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt", "terseLabel": "Proceeds from Debt, Net of Issuance Costs and Repayment of Debt" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from the sale of royalty and milestone rights.", "label": "acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights", "terseLabel": "Proceeds From Sale of Royalty and Milestone Rights" } } }, "localname": "ProceedsFromSaleOfRoyaltyAndMilestoneRights", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents purchases of property and equipment that were acquired through accounts payable.", "label": "Purchases of property and equipment in accounts payable and accrued expenses" } } }, "localname": "PurchasesOfPropertyAndEquipmentInAccountsPayable", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to alleged misstatements as the shareholder.", "label": "Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]" } } }, "localname": "PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.", "label": "Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]" } } }, "localname": "PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "acrx_RSUsESPPAndEmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the antidilutive securities types; restricted stock units, employee stock purchase plan, and employee stock options.", "label": "RSU's, ESPP, and Employee Stock Options [Member]" } } }, "localname": "RSUsESPPAndEmployeeStockOptionsMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "acrx_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents 2021 registered direct offering.", "label": "2021 Registered Direct Offering [Member]" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of additional milestone payments the Company is eligible to receive based upon successful regulatory and product development efforts and net sales target achievements.", "label": "acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets", "terseLabel": "Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets" } } }, "localname": "RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_RoyaltyArrangmentMaximumPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The capped amount of payments of company required to make to PDL.", "label": "acrx_RoyaltyArrangmentMaximumPayments", "terseLabel": "Royalty Arrangment Maximum Payments" } } }, "localname": "RoyaltyArrangmentMaximumPayments", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allowance for sales and returns, discounts, chargebacks and rebates.", "label": "SEC Schedule, 12-09, Allowance, Sales and Returns, Discounts, Chargebacks and Rebates [Member]" } } }, "localname": "SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" ], "xbrltype": "domainItemType" }, "acrx_SWKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents SWK.", "label": "SWK [Member]" } } }, "localname": "SWKMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "domainItemType" }, "acrx_ScheduleOfDeferredTaxAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsTableTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Stock Options Outstanding and Exercisable Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.", "label": "Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shared-based compensation arrangement by share-based payment award equity instrument other than options outstanding.", "label": "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Outstanding (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of additional shares that could be added from expired or cancelled shares already issued under another share-based payment plan.", "label": "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares to be Added (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested and exercisable options (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "sharesItemType" }, "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested and exercisable options, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "durationItemType" }, "acrx_SiteReadinessAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents site readiness agreement.", "label": "Site Readiness Agreement [Member]" } } }, "localname": "SiteReadinessAgreementMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the stock option plan option reserve annual increase as percentage of outstanding shares allowed.", "label": "acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed", "terseLabel": "Stock Option Plan Option Reserve Annual Increase as Percentage of Outstanding Shares Allowed" } } }, "localname": "StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "acrx_SubjectToExpirationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subject to Expiration [Member]" } } }, "localname": "SubjectToExpirationMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "acrx_TaxYears2018To2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax years 2018 to 2020.", "label": "Tax Years 2018 to 2020 [Member]" } } }, "localname": "TaxYears2018To2020Member", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "acrx_The2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2020 equity incentive plan.", "label": "The 2020 Equity Incentive Plan [Member]" } } }, "localname": "The2020EquityIncentivePlanMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "acrx_TimebasedStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents time-based stock option.", "label": "Time-based Stock Option [Member]" } } }, "localname": "TimebasedStockOptionMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "domainItemType" }, "acrx_ToolingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Tooling.", "label": "Tooling [Member]" } } }, "localname": "ToolingMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "acrx_TotalObligationUnderLeaseholdAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents total obligation under leasehold agreement.", "label": "acrx_TotalObligationUnderLeaseholdAgreement", "terseLabel": "Total Obligation Under Leasehold Agreement" } } }, "localname": "TotalObligationUnderLeaseholdAgreement", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "acrx_USGovernmentAgencySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the U.S. Government Agency Securities.", "label": "U.S. Government Agency Securities [Member]" } } }, "localname": "USGovernmentAgencySecuritiesMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "domainItemType" }, "acrx_ValuationAllowancesAndReservesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves [Table Text Block]" } } }, "localname": "ValuationAllowancesAndReservesTableTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" ], "xbrltype": "textBlockItemType" }, "acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to warrant in connection with Oxford finance loan agreement.", "label": "Warrant In Connection with Oxford Finance Loan Agreement [Member]" } } }, "localname": "WarrantInConnectionWithOxfordFinanceLoanAgreementMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "acrx_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of warrants.", "label": "Warrants Disclosure [Text Block]" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants" ], "xbrltype": "textBlockItemType" }, "acrx_WarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants, Policy [Policy Text Block]" } } }, "localname": "WarrantsPolicyPolicyTextBlock", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "acrx_WholesalerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to wholesaler A.", "label": "Wholesaler A [Member]" } } }, "localname": "WholesalerAMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "acrx_WriteoffOfRightofuseAssetAndLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount write-off of right-of-use asset and lease liability.", "label": "Write-off of right-of-use asset and lease liability" } } }, "localname": "WriteoffOfRightofuseAssetAndLeaseLiability", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "acrx_ZALVISOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the product ZALVISO.", "label": "ZALVISO [Member]" } } }, "localname": "ZALVISOMember", "nsuri": "http://www.acelrx.com/20211231", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)" } } }, "localname": "statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Liability Related to Sale of Future Royalties" } } }, "localname": "statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)" } } }, "localname": "statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)" } } }, "localname": "statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation - Option Activity (Details)" } } }, "localname": "statement-statement-note-14-stock-based-compensation-option-activity-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)" } } }, "localname": "statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-14-stock-based-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Stock Based Compensation" } } }, "localname": "statement-statement-note-14-stock-based-compensation-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)" } } }, "localname": "statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 15 - Net Loss Per Share of Common Stock" } } }, "localname": "statement-statement-note-15-net-loss-per-share-of-common-stock-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Accrued Liabilities - Accrued Liabilities (Details)" } } }, "localname": "statement-statement-note-16-accrued-liabilities-accrued-liabilities-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-16-accrued-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Accrued Liabilities" } } }, "localname": "statement-statement-note-16-accrued-liabilities-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 18 - Income Taxes - Net Deferred Tax Assets (Details)" } } }, "localname": "statement-statement-note-18-income-taxes-net-deferred-tax-assets-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)" } } }, "localname": "statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-18-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 18 - Income Taxes" } } }, "localname": "statement-statement-note-18-income-taxes-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)" } } }, "localname": "statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)" } } }, "localname": "statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)" } } }, "localname": "statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Investments and Fair Value Measurement" } } }, "localname": "statement-statement-note-2-investments-and-fair-value-measurement-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-3-inventories-net-inventory-components-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Inventories, Net - Inventory Components (Details)" } } }, "localname": "statement-statement-note-3-inventories-net-inventory-components-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-3-inventories-net-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Inventories, Net" } } }, "localname": "statement-statement-note-3-inventories-net-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-4-property-and-equipment-net-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Property and Equipment, Net" } } }, "localname": "statement-statement-note-4-property-and-equipment-net-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)" } } }, "localname": "statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Revenue From Contracts With Customers" } } }, "localname": "statement-statement-note-7-revenue-from-contracts-with-customers-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)" } } }, "localname": "statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-8-longterm-debt-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Long-term Debt" } } }, "localname": "statement-statement-note-8-longterm-debt-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Leases - Maturities of Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-9-leases-maturities-of-lease-liabilities-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-9-leases-operating-lease-costs-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Leases - Operating Lease Costs (Details)" } } }, "localname": "statement-statement-note-9-leases-operating-lease-costs-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-note-9-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Leases" } } }, "localname": "statement-statement-note-9-leases-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)" } } }, "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "acrx_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.acelrx.com/20211231", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-document-and-entity-information", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details", "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-document-and-entity-information", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details", "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acelrx.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r55", "r57", "r105", "r106", "r239", "r262", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of executive officer.", "label": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r174", "r290", "r295", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r238", "r261", "r318", "r321", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r525", "r528", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r238", "r261", "r318", "r321", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r525", "r528", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r174", "r290", "r295", "r527" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r172", "r290", "r294", "r491", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r172", "r290", "r294", "r491", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r238", "r261", "r298", "r318", "r321", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r525", "r528", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r238", "r261", "r298", "r318", "r321", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r525", "r528", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r56", "r57", "r105", "r106", "r239", "r262" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r124", "r319", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r124", "r128", "r319" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r114", "r570" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" ], "xbrltype": "textBlockItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r124", "r128", "r218", "r319", "r476" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r175", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r22", "r176", "r177" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued and other liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r45" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r203" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquisitionCostsCumulative": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "us-gaap_AcquisitionCostsCumulative", "terseLabel": "Acquisition Costs, Cumulative" } } }, "localname": "AcquisitionCostsCumulative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23", "r362", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r359", "r360", "r361", "r421" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Tax payments related to shares withheld for restricted stock units vested" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r323", "r325", "r365", "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r234", "r274", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "terseLabel": "Net proceeds from issuance of warrants in connection with equity financings" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r325", "r355", "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r77", "r90", "r251", "r448" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Non-cash interest expense related to debt financing", "terseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "us-gaap_AreaOfRealEstateProperty", "terseLabel": "Area of Real Estate Property (Square Foot)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r101", "r155", "r164", "r170", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r413", "r416", "r437", "r471", "r473", "r494", "r513" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r54", "r101", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r413", "r416", "r437", "r471", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r186", "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Short-term investment, amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r183", "r187", "r193", "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Short-term investment, fair value", "terseLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r326", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r317", "r320" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r317", "r320", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r405", "r406", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability, Total" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "us-gaap_CapitalizedContractCostAmortization", "terseLabel": "Capitalized Contract Cost, Amortization" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r36", "r473", "r536", "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash, amortized cost" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r36", "r92" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and cash equivalent, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Total cash, cash equivalents and short-term investments", "terseLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r86", "r92", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "CASH, CASH EQUIVALENTS \u2014End of year", "periodStartLabel": "CASH, CASH EQUIVALENTS \u2014Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r438" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r277", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Commercial paper" } } }, "localname": "CommercialPaperAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r217", "r502", "r518" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r214", "r215", "r216", "r219", "r554" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r421" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value\u2014200,000,000 shares authorized as of December 31, 2021 and 2020; 136,819,647 and 98,812,008 shares issued and outstanding as of December 31, 2021 and 2020, respectively", "terseLabel": "Common Stock, Value, Issued, Ending Balance" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r60", "r62", "r63", "r71", "r505", "r521" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r144", "r145", "r174", "r434", "r435", "r553" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r144", "r145", "r174", "r434", "r435", "r535", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r144", "r145", "r174", "r434", "r435", "r535", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r139", "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r144", "r145", "r174", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r144", "r145", "r174", "r434", "r435", "r553" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r95", "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r279", "r280", "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r279", "r280", "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "us-gaap_ContractWithCustomerLiabilityCurrent", "terseLabel": "Contract with Customer, Liability, Current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r279", "r280", "r291" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "negatedLabel": "In prior periods(1)" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r299", "r313", "r534" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r73", "r491" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r72" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r210", "r211", "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r143", "r174" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r18", "r19", "r100", "r107", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r255", "r256", "r257", "r258", "r451", "r495", "r496", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r235", "r255", "r256", "r449", "r451", "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r47", "r253", "r449", "r451" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48", "r100", "r107", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r255", "r256", "r257", "r258", "r451" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "us-gaap_DebtInstrumentPeriodicPaymentPrincipal", "terseLabel": "Debt Instrument, Periodic Payment, Principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r242", "r448", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "negatedLabel": "Less: Unamortized discount on notes payable" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss", "terseLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r390", "r391" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r383" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r390", "r391" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Section 59(e) R&D expenditures" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r385" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r390", "r391" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r388", "r390", "r391" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Research credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r384" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r90", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r153" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share of common stock, basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r501", "r519" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued compensation and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r65", "r66", "r67", "r116", "r117", "r118", "r120", "r125", "r127", "r136", "r192", "r274", "r276", "r359", "r360", "r361", "r394", "r395", "r421", "r439", "r440", "r441", "r442", "r443", "r444", "r529", "r530", "r531", "r573" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r423", "r424", "r425", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r423", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r244", "r255", "r256", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r313", "r424", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r244", "r299", "r301", "r306", "r313", "r424", "r478" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r244", "r255", "r256", "r299", "r301", "r306", "r313", "r424", "r479" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r244", "r255", "r256", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r313", "r424", "r480" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r428", "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value of contingent put option associated with the Loan Agreement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in fair value of contingent put option associated with the Loan Agreement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Fair value, End of period", "periodStartLabel": "Fair value, Beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r244", "r255", "r256", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r313", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r453" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "us-gaap_GainLossOnTerminationOfLease", "negatedLabel": "Gain on derecognition of operating lease", "terseLabel": "Gain (Loss) on Termination of Lease" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r200", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r69", "r155", "r163", "r166", "r169", "r171", "r493", "r503", "r507", "r522" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r205", "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r102", "r374", "r381", "r387", "r396", "r398", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r126", "r127", "r154", "r372", "r397", "r399", "r523" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "terseLabel": "Income Tax Expense (Benefit), Total", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r64", "r370", "r371", "r381", "r382", "r386", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r373" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r373" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Tax at statutory federal rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r373" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock options" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r373" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r373" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State tax\u2014net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid (refunded)" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "verboseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r89", "r488" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "terseLabel": "Increase (Decrease) in Employee Related Liabilities, Total" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r89", "r462" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "verboseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r68", "r152", "r447", "r450", "r506" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r77", "r249", "r254", "r257", "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpensePolicyTextBlock": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.", "label": "Interest Expense, Policy [Policy Text Block]" } } }, "localname": "InterestExpensePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r85", "r87", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r28", "r197" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r52", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r53", "r96", "r135", "r194", "r196", "r198", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r30", "r197" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r29", "r197" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r195" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory impairment charge", "terseLabel": "Inventory Write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r75", "r77" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Interest income and other income, net" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r466", "r468" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Net lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r8", "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "us-gaap_LeaseholdImprovementsGross", "terseLabel": "Leasehold Improvements, Gross" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r467" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44", "r101", "r165", "r191", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r414", "r416", "r417", "r437", "r471", "r472" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r101", "r191", "r437", "r473", "r497", "r516" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r101", "r191", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r414", "r416", "r417", "r437", "r471", "r472", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r243", "r252", "r255", "r256", "r496", "r514" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-term Debt, Total", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebtCurrent", "negatedLabel": "Less current portion", "terseLabel": "Long-term debt, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term debt, net of current portion", "terseLabel": "Long-term debt, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r222" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "us-gaap_LossContingencyNumberOfDefendants", "terseLabel": "Loss Contingency, Number of Defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money market funds, amortized cost" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r88", "r91" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r59", "r61", "r67", "r70", "r91", "r101", "r119", "r121", "r122", "r123", "r124", "r126", "r127", "r129", "r155", "r163", "r166", "r169", "r171", "r191", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r422", "r437", "r504", "r520" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NONCASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r163", "r166", "r169", "r171" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r460", "r468" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liabilities", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r455" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities, current portion", "negatedLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r455" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r454" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r465", "r468" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average remaining discount rate \u2013 operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r464", "r468" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term \u2013 operating leases (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r45" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r418", "r420" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax", "terseLabel": "OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other liabilities.", "label": "Other Liabilities [Table Text Block]" } } }, "localname": "OtherLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "us-gaap_OtherNoncashIncomeExpense", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "terseLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Tax payments related to shares withheld for restricted stock units vested" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r80", "r409", "r410", "r411" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "us-gaap_PaymentsToAcquireProductiveAssets", "negatedLabel": "Asset acquisition costs" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r81" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "us-gaap_PaymentsToAcquireShortTermInvestments", "negatedLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r298", "r300", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r326", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r34", "r35" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r82" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds from issuance of common stock in connection with equity financings", "terseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r82", "r358" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Net proceeds from issuance of common stock through equity plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r82" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Net proceeds from issuance of warrants in connection with equity financings", "terseLabel": "Proceeds from Issuance of Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity, Total" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r78", "r79", "r184" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from sale of investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r207", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r202" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r204", "r473", "r509", "r517" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r37", "r204", "r555", "r556" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r202" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r178", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r84" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Payment of long-term debt", "terseLabel": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r368", "r490", "r560" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated", "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r90", "r208", "r210", "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "us-gaap_RestructuringCharges", "terseLabel": "Restructuring Charges, Total" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r276", "r362", "r473", "r515", "r532", "r533" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r125", "r127", "r192", "r359", "r360", "r361", "r394", "r395", "r421", "r529", "r531" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r150", "r151", "r162", "r167", "r168", "r172", "r173", "r174", "r289", "r290", "r491" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r293", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r97", "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r463", "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Establishment of right-of-use asset and lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r144", "r174" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r325", "r354", "r364" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r331", "r341", "r344" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r380", "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r142", "r144", "r145", "r146", "r434", "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "terseLabel": "Weighted average grant date fair value, forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Weighted average grant date fair value, granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Restricted stock units outstanding (in shares)", "periodStartLabel": "Restricted stock units outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Restricted stock units weighted average outstanding (in dollars per share)", "periodStartLabel": "Restricted stock units weighted average outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend rate", "terseLabel": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r333", "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of Stock Options Outstanding (in shares)", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)", "periodEndLabel": "Outstanding, weighted-average exercise price (in dollars per share)", "periodStartLabel": "Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and exercisable options, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Shares Subject to Stock Options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and exercisable options, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r324", "r328" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r326", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price Range, Lower Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price Range, Upper Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r349", "r363" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (Year)", "terseLabel": "Derived service period (in years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual LIfe (Year)", "terseLabel": "Outstanding, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r17", "r498", "r499", "r512" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r51", "r65", "r66", "r67", "r116", "r117", "r118", "r120", "r125", "r127", "r136", "r192", "r274", "r276", "r359", "r360", "r361", "r394", "r395", "r421", "r439", "r440", "r441", "r442", "r443", "r444", "r529", "r530", "r531", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details", "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r136", "r491" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables", "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies", "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan", "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement", "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements", "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables", "http://www.acelrx.com/20211231/role/statement-note-9-leases", "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual", "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details", "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details", "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r20", "r21", "r274", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Issuance of common stock upon ESPP purchase (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r274", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Net proceeds from issuance of common stock in connection with equity financings (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r20", "r21", "r274", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "terseLabel": "Restricted stock units vested (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r274", "r276", "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Issuance of common stock upon exercise of stock options (in shares)", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r20", "r21", "r274", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Issuance of common stock upon ESPP purchase" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r274", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "us-gaap_StockIssuedDuringPeriodValueNewIssues", "terseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r274", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "terseLabel": "Restricted stock units vested" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r51", "r274", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r101", "r179", "r191", "r437", "r473" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets", "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r99", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r276", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r461", "r468" ], "calculation": { "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "us-gaap_SubleaseIncome", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r445", "r475" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r445", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r445", "r475" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r474", "r477" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants", "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events", "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables", "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables", "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables", "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables", "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables", "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables", "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables", "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables", "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables", "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes", "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties", "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r104", "r299", "r508" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r369", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Unrecognized benefit\u2014end of period", "periodStartLabel": "Unrecognized benefit\u2014beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Gross increases\u2014current period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Gross increases\u2014prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r137", "r138", "r140", "r141", "r147", "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r108", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "us-gaap_ValuationAllowancesAndReservesBalance", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "Additions" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "us-gaap_ValuationAllowancesAndReservesDeductions", "negatedLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r108", "r109", "r110", "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r108", "r109", "r110", "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-", "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual", "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "us-gaap_WarrantsAndRightsOutstandingMeasurementInput", "terseLabel": "Warrants and Rights Outstanding, Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Shares used in computing net loss per share of common stock, basic and diluted \u2013see Note 15 (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r402": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r477": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10.(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r561": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r563": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r564": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r565": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r566": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r567": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r568": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r569": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r570": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r571": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r572": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" }